Akkermansia Muciniphila for Metabolic and Gut Barrier Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Obesity and related metabolic disorders are associated with metabolic dysfunctions, low-grade inflammatory states, and impaired gut barrier function, for which current treatments are inadequate.
Innovation Solution
The use of Akkermansia muciniphila or fragments thereof to treat metabolic disorders by addressing the underlying dysfunctions of obesity, including metabolic dysfunctions, low-grade inflammatory states, and impaired gut barrier function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for obesity are used, then weight loss may be achieved, but metabolic dysfunctions, inflammatory states, and gut barrier impairment are not adequately addressed
Solution Approach 1:
The patent introduces Akkermansia muciniphila as a mediator organism that acts on the gut microbiota to improve metabolic disorders. This probiotic bacterium serves as an intermediary that directly addresses the underlying dysfunctions (metabolic dysfunction, inflammation, gut barrier impairment) while also contributing to weight loss, thereby resolving the contradiction between achieving weight loss and treating underlying metabolic issues
Solution Approach 2:
The patent employs Akkermansia muciniphila that naturally colonizes the gut and self-regulates metabolic functions. The bacterium performs multiple functions autonomously: improving gut barrier function, reducing inflammation, regulating metabolism, and promoting weight loss without requiring external intervention for each function, thus reliably addressing multiple underlying dysfunctions simultaneously
2Reliability
If Akkermansia muciniphila is used to treat metabolic disorders, then gut barrier function and inflammation are improved, but the complexity of the treatment increases
Solution Approach 1:
The patent utilizes Akkermansia muciniphila as a multi-functional probiotic that simultaneously addresses multiple aspects of metabolic disorders: improving gut barrier function, reducing inflammation, regulating glucose metabolism, and promoting weight loss. This single organism performs multiple therapeutic functions, simplifying the overall treatment approach while comprehensively addressing the complex underlying dysfunctions
Data Source
AI summary
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.